The efficacy of the TNFR2 agonist against the S. aureus skin infection was not due to direct antistaphylococcal activity, as there were no differences in the growth curves of S. aureus incubated with varying concentrations of the TNFR2 agonist (80, 160, and 320 μg/ml) and vehicle control (fig. Here, TNFRSF1B is linked to skin infection.